These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23777493)

  • 1. Pityriasis rubra pilaris-like reaction induced by imatinib.
    Plana A; Carrascosa JM; Vilavella M; Ferrandiz C
    Clin Exp Dermatol; 2013 Jul; 38(5):520-2. PubMed ID: 23777493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A new case of pityriasis rubra pilaris-like eruption associated with ponatinib, a tyrosine kinase inhibitor].
    Krygier J; Leemans G; Forsyth R; de Becker A; Gutermuth J; Grosber M
    Ann Dermatol Venereol; 2018 Nov; 145(11):665-670. PubMed ID: 29903676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pityriasis rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib.
    Jack A; Mauro MJ; Ehst BD
    J Am Acad Dermatol; 2013 Nov; 69(5):e249-e250. PubMed ID: 24124847
    [No Abstract]   [Full Text] [Related]  

  • 4. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate.
    Scheinfeld N
    J Drugs Dermatol; 2006 Mar; 5(3):228-31. PubMed ID: 16573254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib: a designer drug, another cutaneous complication.
    Dickens E; Lewis F; Bienz N
    Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate-induced pseudoporphyria in two children.
    Mahon C; Purvis D; Laughton S; Bradbeer P; Teague L
    Pediatr Dermatol; 2014; 31(5):603-7. PubMed ID: 24920470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pityriasis Rubra Pilaris-Like Reaction Induced by a Tyrosine Kinase Inhibitor, the Ponatinib.
    Mongereau M; Hillion B; Fouillard L; Boivin JF; Gaudron S
    Am J Dermatopathol; 2021 May; 43(5):394-395. PubMed ID: 33264130
    [No Abstract]   [Full Text] [Related]  

  • 8. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors.
    Severino G; Chillotti C; De Lisa R; Del Zompo M; Ardau R
    Ann Pharmacother; 2005 Jan; 39(1):162-4. PubMed ID: 15546944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pityriasis rosea associated with imatinib (STI571, Gleevec).
    Konstantopoulos K; Papadogianni A; Dimopoulou M; Kourelis C; Meletis J
    Dermatology; 2002; 205(2):172-3. PubMed ID: 12218236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Imatinib plasma levels in the management of cutaneous side effects induced by imatinib (Glivec®): 2 case reports].
    Trabelsi S; Gaïes E; Sraïri S; Sahnoun R; Daghfous R; Lakhal M; El Aïdli S; Klouz A
    Ann Biol Clin (Paris); 2013; 71(2):203-6. PubMed ID: 23587588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudoporphyria induced by imatinib mesylate.
    Pérez NO; Esturo SV; Viladomiu Edel A; Moreno AJ; Valls AT
    Int J Dermatol; 2014 Feb; 53(2):e143-4. PubMed ID: 23451912
    [No Abstract]   [Full Text] [Related]  

  • 12. Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine.
    Hunjan MK; Roberts C; Karim S; Hague J
    Clin Exp Dermatol; 2022 Jan; 47(1):188-190. PubMed ID: 34379821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pityriasis rubra pilaris with focal acantholytic dyskeratosis during treatment with imiquimod 5% cream].
    Gómez-Moyano E; Crespo-Erchiga A; Vera Casaño A; Sanz Trelles A
    Actas Dermosifiliogr; 2010 Dec; 101(10):898-900. PubMed ID: 21159271
    [No Abstract]   [Full Text] [Related]  

  • 14. Stevens-Johnson syndrome after treatment with STI571: a case report.
    Hsiao LT; Chung HM; Lin JT; Chiou TJ; Liu JH; Fan FS; Wang WS; Yen CC; Chen PM
    Br J Haematol; 2002 Jun; 117(3):620-2. PubMed ID: 12028031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib-induced pseudoporphyria.
    Timmer-de Mik L; Kardaun SH; Kramer MH; Hayes DP; Bousema MT
    Clin Exp Dermatol; 2009 Aug; 34(6):705-7. PubMed ID: 19077095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir-Induced Erythrodermic Pityriasis Rubra Pilaris-Like Drug Eruption.
    Cheung EJ; Jedrych JJ; English JC
    J Drugs Dermatol; 2015 Oct; 14(10):1161-2. PubMed ID: 26461830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs associated with development of pityriasis rubra pilaris: A systematic review.
    Mufti A; Lytvyn Y; Maliyar K; Sachdeva M; Yeung J
    J Am Acad Dermatol; 2021 Apr; 84(4):1071-1081. PubMed ID: 32687965
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature.
    Park MA; Volcheck GW; Guarderas JC
    Allergy Asthma Proc; 2004; 25(5):345-7. PubMed ID: 15603208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib induced pyoderma gangrenosum.
    Pinato DJ; Sharma R
    J Postgrad Med; 2013; 59(3):244-5. PubMed ID: 24029213
    [No Abstract]   [Full Text] [Related]  

  • 20. Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition.
    Dewan AK; Sowerby L; Jadeja S; Lian C; Wen P; Brown JR; Fisher DC; LeBoeuf NR
    Clin Exp Dermatol; 2018 Dec; 43(8):890-894. PubMed ID: 29851132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.